Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H (HK:0874)
:0874
Want to see HK:0874 full AI Analyst Report?
Top Page
Guangzhou Baiyunshan Pharmaceutical Holdings Company
(0874)
Select Model
Select Model
Rating:56Neutral
Price Target:
HK$17.00
â–¼(-9.33% Downside)
Action:ReiteratedDate:04/28/26
The score is held back primarily by weakening cash generation and margin compression despite strong revenue growth, alongside a bearish technical setup below key moving averages. These risks are partly offset by an attractive valuation (low P/E) and a high dividend yield.
Positive Factors
Strong Revenue Growth
TTM revenue up ~77% reflects sustained demand and successful distribution of core products across channels. Durable top-line expansion increases scale, supports longer-term investment in R&D and distribution, and provides a platform to recover margins if cost control improves.
Negative Factors
Weak Cash Generation
The swing to negative FCF in 2025 and only modest positive TTM FCF signals deteriorating cash conversion. This reduces internal funding for capex, R&D, and dividends, increases reliance on external financing, and raises earnings-quality risk that can constrain strategy over multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
TTM revenue up ~77% reflects sustained demand and successful distribution of core products across channels. Durable top-line expansion increases scale, supports longer-term investment in R&D and distribution, and provides a platform to recover margins if cost control improves.
Read all positive factors
Guangzhou Baiyunshan Pharmaceutical Holdings Company (0874) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$39.99B
Dividend Yield7.15%
Average Volume (3M)908.48K
Price to Earnings (P/E)8.9
Beta (1Y)0.65
Revenue Growth7.32%
EPS Growth12.84%
CountryHK
Employees28,138
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.26
Shares Outstanding219,900,000
10 Day Avg. Volume928,235
30 Day Avg. Volume908,476
Financial Highlights & Ratios
PEG Ratio3.10
Price to Book (P/B)0.68
Price to Sales (P/S)0.34
P/FCF Ratio-27.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.99
Revenue Forecast (FY)HK$82.57B
Guangzhou Baiyunshan Pharmaceutical Holdings Company Business Overview & Revenue Model
Company Description
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medic...
How the Company Makes Money
The company makes money primarily by (1) selling medicines and healthcare products it manufactures and (2) distributing pharmaceuticals and related products through wholesale and retail channels. Revenue from manufacturing is generated when Baiyun...
Guangzhou Baiyunshan Pharmaceutical Holdings Company Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
66
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 78.01B | 75.44B | 74.99B | 75.52B | 70.79B | 69.01B |
| Gross Profit | 12.50B | 11.45B | 12.52B | 14.19B | 13.28B | 13.23B |
| EBITDA | 3.81B | 3.95B | 4.90B | 6.49B | 6.22B | 5.82B |
| Net Income | 2.93B | 2.91B | 2.84B | 4.06B | 3.97B | 3.72B |
Balance Sheet | ||||||
| Total Assets | 89.46B | 84.55B | 81.68B | 78.59B | 74.67B | 66.12B |
| Cash, Cash Equivalents and Short-Term Investments | 12.29B | 23.81B | 22.72B | 21.31B | 22.56B | 22.38B |
| Total Debt | 18.57B | 20.70B | 12.37B | 11.70B | 11.43B | 9.92B |
| Total Liabilities | 47.71B | 43.40B | 43.91B | 41.91B | 41.03B | 34.79B |
| Stockholders Equity | 39.43B | 37.80B | 35.90B | 34.92B | 32.07B | 29.06B |
Cash Flow | ||||||
| Free Cash Flow | 666.92M | -954.34M | 2.31B | 2.48B | 5.62B | 4.42B |
| Operating Cash Flow | 1.91B | 253.50M | 3.44B | 4.10B | 7.00B | 5.67B |
| Investing Cash Flow | -6.76B | -3.81B | -5.96B | -3.11B | -7.25B | -931.57M |
| Financing Cash Flow | 2.03B | -98.13M | -1.01B | -1.98B | 45.95M | -1.49B |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Technical Analysis
Negative
18.75
Price Trends
18.30
Negative
18.50
Negative
18.32
Negative
Market Momentum
-0.41
Negative
34.78
Neutral
28.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0874, the sentiment is Negative. The current price of 18.75 is above the 20-day moving average (MA) of 17.29, above the 50-day MA of 18.30, and above the 200-day MA of 18.32, indicating a bearish trend. The MACD of -0.41 indicates Negative momentum. The RSI at 34.78 is Neutral, neither overbought nor oversold. The STOCH value of 28.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0874.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$23.29B | 22.15 | 7.26% | 3.13% | 5.48% | -49.67% | |
72 Outperform | HK$30.61B | 9.36 | 14.47% | 4.09% | 1.48% | -1.55% | |
63 Neutral | HK$32.62B | 19.33 | 8.60% | 2.26% | 10.00% | -7.54% | |
61 Neutral | HK$36.31B | 6.37 | 7.91% | 2.95% | 4.66% | 20.77% | |
57 Neutral | HK$72.71B | 14.15 | 7.02% | 1.69% | 1.52% | 22.54% | |
56 Neutral | HK$39.99B | 8.90 | 7.89% | 7.15% | 7.32% | 12.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
16.52
0.48
2.98%
HK:0867
China Medical System Holdings
13.06
5.15
65.11%
HK:1513
Livzon Pharmaceutical Group
28.20
2.96
11.73%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
19.71
5.23
36.15%
HK:3320
China Resources Pharmaceutical Group Ltd.
5.29
0.50
10.48%
HK:0512
Grand Pharmaceutical Group Limited
6.34
0.55
9.50%
Guangzhou Baiyunshan Pharmaceutical Holdings Company Corporate Events
Baiyunshan Q1 Revenue Rises as Profit Margins Narrow and Cash Outflows Ease
Apr 27, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings reported first-quarter 2026 operating revenue of RMB23.28 billion, up 3.58% year on year, while net profit attributable to shareholders slipped 2.06% to RMB1.78 billion as total profit edged down 1.04%....
Guangzhou Baiyunshan Pharma Sets Board Meeting to Review Q1 2026 Results
Apr 14, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has scheduled a board meeting for 27 April 2026 in Guangzhou, where directors will review and approve the unaudited financial results for the three months ended 31 March 2026. The sessio...
Guangzhou Baiyunshan Proposes 2025 Cash Dividend After Solid Earnings
Mar 20, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company reported that its 2025 financial statements, prepared under China Accounting Standards for Business Enterprises and audited with an unqualified opinion by WUYIGE Certified Public Accountants, sh...
Guangzhou Baiyunshan Proposes Final 2025 Cash Dividend of RMB 0.45 Per Share
Mar 20, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has announced a proposed final ordinary cash dividend of RMB 0.45 per share for the financial year ended 31 December 2025. Key dates and details, including the Hong Kong dollar equivalen...
Guangzhou Baiyunshan Sets March 2026 Board Meeting for 2025 Results
Mar 10, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company has scheduled a board meeting for 20 March 2026 to review and approve its audited consolidated financial results for the year ended 31 December 2025. The meeting may also address other business ...
Guangzhou Baiyunshan Announces Vice Chair Resignation and Change of Authorised Representative
Mar 6, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings announced that vice chairperson and executive director Ms. Cheng Ning has resigned from all her positions, including as a member of the Budget Committee and as an authorised representative under Hong Ko...
Guangzhou Baiyunshan Sets Out Board Lineup and Committee Roles
Mar 6, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has disclosed the current composition of its board, led by chairperson Li Xiaojun and vice chairperson Chen Jiehui, comprising five executive directors and four independent non-executive...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.